SPHK2 and malignant colon neoplasm: ABC294640 (3-(4-chlorophenyl)-N-(4-pyridinylmethyl)-tricyclo (3.3.1.13,7) decane-1-carboxamide), a first-in-class sphingosine kinase 2 (SphK2) inhibitor undergoing clinical trials, has shown promising results in reversing chemoresistance in colon cancer.